XNAS · Laboratory Analytical Instruments · S&P 500
$1.97
+$0.09 (+4.79%) today
Open $1.88 High $1.99 Low $1.83 Vol 5,386K Avg $1.94
Find similar stocks by technical condition — S&P 500 universe
| Symbol | Company Name | Exchange | Currency | Category |
|---|---|---|---|---|
| LIMN | Liminatus Pharma, Inc. Class A Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| CMPX | Compass Therapeutics, Inc. Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| EXOZ | eXoZymes Inc. Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| PHGE | BiomX Inc. | XASE | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| SANA | Sana Biotechnology, Inc. Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| SGMO | Sangamo Therapeutics, Inc. Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| PCVX | Vaxcyte, Inc. Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| TECH | Bio-Techne Corp. | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| CELZ | Creative Medical Technology Holdings, Inc. Common Stock | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| MGTX | MeiraGTx Holdings plc Ordinary Shares | XNAS | USD | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
52-week price range
Price is 0.0% above its 52-week low and 0.0% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.